One platform for all researcher needs
AI-powered academic writing assistant
Your #1 AI companion for literature search
AI tool for graphics, illustrations, and artwork
Unlock unlimited use of all AI tools with the Editage All Access membership.
Explore Editage All Access
Open Accesshttps://doi.org/10.1182/blood-2021-152225
Copy DOI Journal: Blood |  Publication Date: Nov 5, 2021 |
 Citations: 2 |
Affiliation: Jewish General Hospital, University of Alabama at Birmingham, University of Michigan–Ann Arbor, The Ohio State University, City Of Hope National Medical Center, Centre Hospitalier de l’Université de Montréal, Takeda (United States), University Hospitals of Cleveland, Case Western Reserve UniversityTAK-981, a First-in-Class SUMO-Activating Enzyme Inhibitor, Combined with Rituximab in Adult Patients (Pts) with CD20-Positive Relapsed/Refractory (R/R) Non-Hodgkin Lymphoma (NHL): Phase 1 Data
Sign-in/Register to access full text options 
Free) Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
